Inhibiting amyloidogenic APP processing, e.g., by targeting the Aβ-generating secretases has been a major focus of AD research over last two decades (e.g., Yan and Vassar, 2014; Geldenhuys and Darvesh, 2015) and several advanced BACE inhibitors are in phase 3 clinical trials (Cumming et al., 2012). This evidence concerns the gene BACE1 and Alzheimer disease.